# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Gilda Radner (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML026-SYN
- Date: 2026-04-06
- Fictional facility: St. Posthumous Health Center
- Fictional author: Delia Marchand, MD
- Calendar frame: modern shifted

## What we are working on

- Four weeks of bloating that makes her clothes tight, feeling full after a few bites, a dull ache low in the abdomen and pelvis, and passing urine more often, on most days; she has been more tired than usual for longer than that **S**
- Afraid this is cancer: her father died of a brain tumor and ovarian cancer runs in her family; she wants to be taken seriously and told plainly **S**

## Your goals

- Tissue diagnosis and gynecologic oncology plan within two weeks of presentation. Target: 2026-04-14. Recorded outcome: Ultrasound, CT and biopsy within four days; diagnosis and consultation on the eighth day. **S**
- Cytoreductive surgery with no visible residual disease within three weeks of diagnosis. Target: 2026-05-12. Recorded outcome: Complete gross resection one week after the diagnosis. **S**
- Six cycles of carboplatin and paclitaxel every three weeks without a delay of more than one week. Target: 2026-09-15. Recorded outcome: Six cycles completed on schedule; CT shows no evidence of disease and CA-125 is 9. **S**
- Germline and tumor genetic results available before the maintenance decision. Target: 2026-09-15. Recorded outcome: Germline panel negative; tumor BRCA1 pathogenic variant; olaparib started. **S**
- PHQ-9 below 10 throughout treatment, with a peer-support connection. Target: 2026-09-15. Recorded outcome: PHQ-9 between 3 and 7; attends a cancer support community group. **S**

## What we agreed to do

- Urgent gynecologic oncology consultation for a suspected ovarian cancer, before any surgery, to confirm the diagnosis and plan primary treatment. Guideline: NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 4.2026 (2026); Committee Opinion No. 716: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk (2017) **S**
- At the first visit: the ovarian cancer symptom index, an abdominal and pelvic examination, CA-125 with CEA, blood count and chemistry, and a urine pregnancy test; transvaginal ultrasound and CT of the chest, abdomen and pelvis within the week, and image-guided biopsy if the scan shows disease outside the pelvis. Guideline: NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 4.2026 (2026); Goff BA, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007;109(2):221-227 (2007); Committee Opinion No. 716: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk (2017) **S**
- Genetic counseling and germline multigene panel testing (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 and the Lynch syndrome genes), as for every woman with epithelial ovarian cancer, and tumor testing for BRCA1 and BRCA2 and homologous recombination deficiency on the surgical specimen; if a germline variant is found, a family letter offering cascade testing to blood relatives. Guideline: NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 4.2026 (2026); Konstantinopoulos PA, et al. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J Clin Oncol 2020;38(11):1222-1245 (2020) **S**
- Primary cytoreductive surgery by gynecologic oncology aiming for no visible residual disease, with enoxaparin for four weeks after the operation. Guideline: NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 4.2026 (2026); Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (2023) **S**
- Carboplatin (AUC 5) and paclitaxel 175 mg/m2 every three weeks for six cycles, starting three weeks after surgery, after hepatitis B, hepatitis C and HIV screening; a three-drug antiemetic regimen on each treatment day; blood counts, kidney function and magnesium before each cycle; CA-125 each cycle; and neuropathy checks at every visit. Guideline: NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 4.2026 (2026); Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020;38(24):2782-2797 (2020); Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348 (2020); Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol 2020 (2020) **S**
- Olaparib 300 mg twice daily as maintenance for two years after a complete response to platinum chemotherapy, chosen because the tumor carries a BRCA1 pathogenic variant; blood count monthly for the first year, with checks for fatigue, nausea, breathlessness and new cough. Guideline: NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 4.2026 (2026); Tew WP, et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J Clin Oncol 2020;38(30):3468-3493 (2020) **S**
- Surgical menopause: symptom review at each visit, non-hormonal measures, a discussion of menopausal hormone therapy at the end of treatment, and a baseline bone density scan. Guideline: NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 4.2026 (2026); Salani R, et al. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 2017;146(1):3-10 (2017) **S**
- Distress and depression screening at each visit, plain information, a cancer support community group, and survivorship care after treatment: a visit every three months for two years with examination and CA-125, and imaging only for symptoms or a rising CA-125. Guideline: NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 4.2026 (2026); Salani R, et al. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 2017;146(1):3-10 (2017) **S**

## Follow-up

- 2026-04-06: Four weeks of bloating, early fullness and pelvic pain in a woman of 39: symptom index, pelvic examination, CA-125, and same-week imaging **S**
- 2026-04-14: Biopsy result: ovarian cancer; gynecologic oncology consultation, genetic counseling, and preparation for surgery **S**
- 2026-05-12: Review three weeks after cytoreductive surgery: pathology, genetic results, and the first cycle of chemotherapy **S**
- 2026-07-14: Midpoint of chemotherapy: CA-125, blood counts, neuropathy, and menopausal symptoms **S**
- 2026-09-15: End of chemotherapy: CT and CA-125 response, and the start of olaparib maintenance **S**
- 2026-10-13: Periodic adult preventive visit after ovarian cancer treatment **S**

This teaching document does not replace care from a qualified clinician.
